Grandomics Biosciences

Grandomics is a pioneer in third-generation sequencing big data technology and applications. Founded on August 8, 2011, it initially used the brand "Future Genomics" to promote third-generation sequencing technology services. It is a third-generation sequencing service company and a third-generation sequencing big data diagnostics company. For many years, it has been focusing on technology development and application expansion on third-generation sequencing platforms. At present, it has formed four major business modules: "Technology Services", "Medical Diagnostics", "Bioinformatics", and "Advanced Manufacturing"; it has built a total of more than 5,000 square meters of scientific research service platforms and medical testing laboratories in Beijing and Wuhan; it has introduced internationally advanced technology platforms such as ONT PromethION 48, PacBio Sequel II, MGISEQ2000/T7, and Bionano Saphyr optical mapping. The company insists on technological innovation and has independently developed the NextDenovo/NextPolish series of third-generation sequencing assembly software, the GrandVariants (GrandSV/GrandSTR, etc.) third-generation sequencing genome variation analysis system software, the GrandPathogen pathogenic microorganism detection software, the GrandBox genetic disease big data analysis system software, SCAN-seq third-generation sequencing single-cell sequencing technology, Grand-C next-generation three-dimensional genomics technology, and the dbSV human genome structural variation database; at the same time, it has built a Huawei Cloud third-generation sequencing high-performance computing cluster to provide customers with high-quality third-generation sequencing analysis and storage services. The company's core team consists of senior experts in third-generation sequencing technology and applications with many years of experience, and more than 50% of them hold master's or doctoral degrees. In the 2020-2024 Nature Index annual rankings, Grandomics was listed for consecutive years. From 2019 to 2022, it was consecutively awarded "Future Healthcare 100 - China Medical Services Top 100". In 2024, it was recognized as a "Five-Star High-Tech Enterprise" by Wuhan. The company has successively received investments from well-known domestic investment institutions such as Matrix Partners China, SAIF Partners, Zero2IPO Capital, Yuanyi Capital, and Chang Development Investment, becoming a high-quality brand in China's third-generation sequencing sector.